Advertisement
New Zealand Markets closed
  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     
  • NZD/USD

    0.6024
    -0.0010 (-0.1626%)
     
  • NZD/EUR

    0.5584
    -0.0009 (-0.17%)
     
  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     
  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     
  • OIL

    79.80
    +0.54 (+0.68%)
     
  • GOLD

    2,373.70
    +33.40 (+1.43%)
     
  • NASDAQ

    18,113.46
    +28.46 (+0.16%)
     
  • FTSE

    8,429.71
    +48.36 (+0.58%)
     
  • Dow Jones

    39,387.76
    +331.36 (+0.85%)
     
  • DAX

    18,808.79
    +122.19 (+0.65%)
     
  • Hang Seng

    18,974.92
    +437.11 (+2.36%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • NZD/JPY

    93.7340
    -0.0340 (-0.04%)
     

Better Buy: Eli Lilly vs. Johnson & Johnson

Better Buy: Eli Lilly vs. Johnson & Johnson

As two of the largest healthcare companies in the world, both Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) have a role to play in well-balanced healthcare portfolios. With a profit margin of 23.8%, 15.1% year-over-year quarterly revenue growth, and trailing-12-month revenues of $23.1 billion, Eli Lilly exudes success.